Wells Fargo raised the firm’s price target on Gracell (GRCL) to $10 from $7 and keeps an Overweight rating on the shares. The firm sees the proposed acquisition of Gracell by AstraZeneca (AZN) as a win-win, greatly accelerating value creation from GC012F in multiple myeloma and systemic lupus erythematosus, and providing the latter with key presence in cell therapy with a differentiated CAR-T platform.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on GRCL:
- M & A News: Bristol-Myers Squibb (NYSE:BMY) to Buy RayzeBio for $4.1B
- M & A News: AstraZeneca (NASDAQ:AZN) to Acquire Gracell for $1.2B
- Gracell jumps 61% to $9.97 after AstraZeneca buyout agreement
- AstraZeneca to acquire Gracell in $1.2B transaction
- Gracell Biotechnologies to be acquired by AstraZeneca, furthering cell therapy ambition across oncology and autoimmune diseases